Creo Medical Group (LSE:CREO) reported revenue of c.60% growth in the quarter ended 31 March, the upper limit of management’s expectations, reinforcing the group’s guidance for 40% to 60% full‑year revenue growth during FY26.
Commercial adoption of its minimally invasive electrosurgical portfolio continues, the company said, supported by excellent clinical validation. Growth momentum follows an earlier trading update on 20 January.
Following the 16 April announcement to sell and outsource its manufacturing operations, Creo expects to reduce underlying operating costs by 15% on an annualised basis compared with FY25. Management frames the move as part of wider efficiency measures to convert top‑line progress into improved operating leverage.
"The company is on track to deliver 40% to 60% full year revenue growth during FY 2026." it added.
Creo expects to publish its full‑year results for 2025 in May 2026.
